Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

Clinical trial NCT03205891 · WITHDRAWN

Trial details

NCT number: NCT03205891
Sponsor: M.D. Anderson Cancer Center
Status: WITHDRAWN
Phase: Phase 1
Study type: INTERVENTIONAL

Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic Classical Hodgkin Lymphoma Anaplastic Large Cell Lymphoma CD30+ Peripheral T-cell Lymphoma

Start date: 2018-03-01
Primary completion: 2021-03-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.